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 College oAbstract Recently, stem cell based cell therapy has become a realistic option to replace damaged
cardiomyocytes. Most studies on stem cell transplantation therapy have focused on the use of undif-
ferentiated stem cells. There is a strong possibility that some cardiogenic differentiation of the stem
cell in vitro prior to transplantation would result in higher engraftment efﬁciency, as well as
enhanced myocardial regeneration and recovery of heart function. In this study we aimed to deﬁne
the conditions for ex-vivo differentiation of cord blood stem cells to cardiomyocytes and endothelial
cells. These conditions include the combination of vascular endothelial growth factor (VEGF);
basic ﬁbroblast growth factor (FGF-2) and platelet derived growth factor AB (PDGF-AB). Forty
cord blood samples were included in this work. In this work, the percentage of CD34+ cells,
CD31+ cells and CD34/31+ cells in mononuclear cells (MNC) suspension was counted prior to
culture (day zero), and day 10 in the different growth factor cocktails used as well as the control
tube, from which the fold increase of CD34+ cells, CD31+ cells and CD34/31+ cells was calcu-
lated. Detection of cardiac troponin I in the cultured cells to conﬁrm cardiac differentiation was
done at day 10 using Mouse anti-troponin I monoclonal antibody. From the present study, it
was concluded that the growth factor cocktail in protocol 2 (FGF2+VEGF+PDGF-AB) gives
better in vitro trans-differentiation of stem/progenitor cells in umbilical cord blood into cardiomyo-
cytes and endothelial cells than the cytokines cocktail in protocol 1 (FGF2+VEGF) alone.
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44 R.A.M. Khattab et al.Introduction
Coronary artery diseases, i.e. acute myocardial infarction and
ischemic cardiomyopathy, are the main causes of death in most
of the developed countries and are a major socioeconomic
healthcare problem. Despite improved pharmacological ther-
apy and coronary revascularization procedures by either per-
cutaneous coronary intervention (PCI) or coronary artery
bypass surgery (CABG) there is still a major need for novel
therapeutic approaches [9].
It has, therefore, been a challenge in clinical research to
ﬁnd new treatment modalities that aim to reduce and repair
the myocardial damage and improve blood supply to the
myocardium in the ischemic heart. The study of regenerative
medicine with vascular growth factor and stem cell therapy
within the last decennium was of great interest and has been
tested in clinical trials in patients with ischemic heart dis-
ease. The aim of this study was to induce the growth of
new blood vessels or the replacement of damaged myocar-
dial cells either directly by transdifferentiation of stem cells
or by a paracrine effect of cytokines secreted from the stem
cells [6].
In the absence of effective endogenous repair mechanisms
after cardiac injury, cell-based therapies have rapidly emerged
as a potential novel therapeutic approach in ischemic heart dis-
ease. A variety of stem and progenitor cells from different
sources have been examined for their potential to promote car-
diac repair and regeneration. At this stage, further optimiza-
tion of cell-based therapy is urgently needed, and ﬁnally,
large-scale clinical trials are required to eventually proove its
clinical efﬁcacy with respect to outcomes, i.e. morbidity and
mortality [15].
Recently, cord blood (CB) is considered an important
source of many types of stem cells, including haematopoietic
stem cells (HSCs), endothelial progenitors, mesenchymal stem
cells (MSCs), very small embryonic/epiblast-like (VSEL) stem
cells, and unrestricted somatic stem cells (USSC), potentially
suitable for use in regenerative medicine [13].
The transplantation studies carried out have demonstrated
that: (i) CB is an alternative source to the marrow of HSCs of
relatively easy procurement, with no-risk for mothers or do-
nors, and with a low risk of transmitting infectious diseases;
(ii) the number of CB cells available for transplantation is
the most important factor for engraftment; and (iii) some de-
gree of HLA mismatch is tolerated [4].
As cell therapy is a promising treatment modality to im-
prove the management of cardiovascular diseases, we per-
formed a study to deﬁne the optimal conditions for the
in vitro trans-differentiation of umbilical cord blood derived
stem cells into cardiomyocytes and endothelial cells.
In the present work, the percentage of CD34+ cells
and CD34+/31+ cells in MNC suspension was estimated
prior to culture (day zero), and after day 10 in the cardio-
genic induction media with different cocktails of cardiogenic
inducers as well as the control tube, from which the fold
increase of CD34+ cells and CD34+/31+ cells was
calculated.
Cardiogenic differentiation was proved by the detection of
cardiac troponin I in the cultured cells at day 10 by immuno-
histochemical staining using Mouse anti-troponin I monoclo-
nal antibody [7].Materials and methods
Umbilical cord blood collection
The present study included 40 umbilical cord blood samples
collected from the obstetric ward of the Kasr Al-Ainy Hospital
during the period from January to September 2007. Only full
term, completely normal, singleton pregnancies were included
in this study.
Umbilical cord blood samples were obtained from the
umbilical vein with the placenta in utero after fetal delivery.
The cord was cleansed with betadine (bovidine iodine) and
alcohol. About 10–15 ml of cord blood was collected under
completely aseptic conditions on preservative free heparin
(GIBCO) in a concentration of 10 IU/ml.Mononuclear cell isolation and culture
The umbilical cord blood was diluted 1:2 with RPMI 1640
medium (GIBCO), layed over Ficoll-Hypaque (Biochrom
KG) for density gradient separation (density 1.077), and cen-
trifuged at 1500 rpm for 30 min. Light density mononuclear
cell layer (Buffy coat) was collected by a sterile Pasteur pipette,
washed with Hanks solution (GIBCO) twice, and then re-sus-
pended in RPMI 1640.
Mononuclear cell counting was performed by automated
cell counters. Viability testing was determined by trypan blue
and found to be more than 95% for all cases prior to culture.
Ex-vivo culture was started immediately after MNC
preparation.
Mononuclear cells in a concentration of 1000.000/ml
were suspended in nutrient medium RPMI 1640 (800 ul,
GIBCO), supplemented with FCS (20 ul/ml, Lab technol-
ogy/Promega), L-Glutamine (40 ul/ml, GIBCO), antibiotic–
antimycotic (20 ul/ml, GIBCO). The tissue culture tubes
were incubated in 5% CO2 at 37 C, for 7 days then the
media were changed and re-incubated to complete10 days
of culture.
Forty cases were subjected to short term culture (for 7–
10 days) in static liquid culture medium under the following
conditions:
– Group I: Cultures with the nutrient medium devoid of car-
diogenic inducers (as a control group).
– Group II: Cultures with the nutrient medium supplemented
with two cardiogenic and angiogenic inducers; basic ﬁbro-
blast growth factor (bFGF) (10 ng/ml, R&D Systems) and
Vascular endothelial growth factor (VEGF) (20 ng/ml,
R&D Systems).
– Group III: Cultures with the nutrient medium with three
cardiogenic and angiogenic inducers which are bFGF
(10 ng/ml), VEGF (20 ng/ml) and Platelet derived growth
factor-AB (PDGF-AB) (10 ng/ml, R&D Systems) which is
added on 3rd day [2].
The degree of differentiation was evaluated by the percent-
age of CD34+ cells and CD34+/CD31+ cells by
ﬂowcytometer.
Cell viability was determined with trypan blue exclusion
test and found to be more than 90% for all culture tubes.
Table 1 The percentage of CD34+ cells in mononuclear cell
suspension at day zero and day 10 of ex-vivo expansion of cord
blood stem cells.
Culture number % CD34+ cells
Day 0 Day 10
Initial count Control Tube 1 Tube 2
Mean 4.14 6.19 14.45 9.66
SD 3.81 6.27 13.09 7.36
Figure 1 The percentage of CD34+ cells in MNC suspension
prior to culture.
Figure 2 The percentage of CD34+ cells at day10.
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ﬁrm cardiac differentiation.
Flowcytometric analysis of cord blood stem cells
Cord blood mononuclear cells before and after expansion cul-
ture were incubated with FITC-conjugated anti-CD34 anti-
bodies (DAKO) and PE-conjugated anti- CD31 antibodies
(DAKO) for 30 min at 4 C. After two washes with phosphate
buffered saline (PBS) (Sigma Aldrich) cells were subsequently
analyzed on FACS scan ﬂowcytometer (Becton Dickinson).
The results were expressed as a percentage of positive
events in relation to all events acquired by the gating [11].
Immunohistochemistry for the detection of cardiac troponin I in
the cultured cells
MNCs for immunostaining were prepared on cytospin slides
and stained for cardiac troponin T (Mouse anti-troponin I
monoclonal antibody, Biomeda) visualized with a Peroxidase
labeled polymer conjugated to goat anti-mouse immunoglobu-
lins (Dako EnVision+ System-HRP, DAB). All studies were
performed in triplicate using samples from different culture
preparations and the results are expressed as a percentage of
peroxidase positive cells/100 cells. Control stainings were per-
formed without primary antibody.
Statistics
Data were presented as mean ± SD. Differences were tested
for statistical signiﬁcance by the Student’s unpaired t test. A
value of p< 0.05 was considered signiﬁcant.
Results
In the current study, we aimed to develop an appropriate dif-
ferentiation medium for in vitro trans-differentiation of umbil-
ical cord blood derived stem cells into cardiomyocytes and
endothelial cells. These media included the combination of dif-
ferent cardiogenic inducers such as VEGF; FGF-2 and PDGF-
AB.
The present study was conducted on 40 umbilical cord
blood (UCB) samples collected from the Obstetric ward of
the Kasr Al-Aini Teaching Hospital, Faculty of Medicine,
Cairo University. Only full term, completely normal, singleton
pregnancies were included. Each cord blood sample was ob-
tained from the umbilical vein of the unborn placenta after fe-
tal delivery.
Flow cytometric enumeration of CD34+ cells in UCB-
mononuclear cell suspension at day zero and at day 10 (Ta-
ble 1, Figs. 1 and 2):
Statistical comparison between the percentage of CD34+
cells prior to culture (day zero) and after 10 days in cardiogenic
differentiation media is shown in Table 2.
There was a statistically signiﬁcant increase in the mean va-
lue of the percentage of CD34+ cells on comparing day zero
to day 10 in all the cocktails used as well as the control tube.
Table 3 shows a statistical comparison between the percent-
age of CD34+ cells in the control tube versus protocols 1 and
2 after 10 days in cardiogenic differentiation media.There was a statistically signiﬁcant increase in the mean va-
lue of CD34+ cells on comparing the control tube at day 10 to
the cocktails used in tubes 1 and 2, and there was a statistically
signiﬁcant decrease in the mean value of CD34+ cells between
protocol 1 and protocol 2.
Flow cytometric enumeration of CD34+/CD31+ cells in
UCB-mononuclear cell suspension at day zero and day 10
(Table 4, Figs. 3 and 4):
Table 2 Statistical comparison between the percentage of CD34+ cells in prior to culture (day zero) and at day 10.
Mean Std. deviation p Value
Control tube %CD34+ cells, day zero 4.14 3.81 <0.001
%CD34+ cells, control, day 10 6.19 6.27
Protocol 1 (tube 1) %CD34+ cells, day zero 4.14 3.81 <0.001
%CD34+ cells, tube 1, day 10 14.45 13.09
Protocol 2 (tube 2) %CD34+ cells, day zero 4.14 3.81 <0.001
%CD34+ cells, tube 2, day 10 9.66 7.36
Table 3
Mean Std. deviation Signiﬁcance (p value)
Control tube versus protocol 1 %CD34+ cells, control, day 10 6.19 6.27 <0.001
%CD34+ cells, tube 1, day 10 14.45 13.09
Control tube versus protocol 2 %CD34+ cells, control, day 10 6.19 6.27 <0.001
%CD34+ cells, tube 2, day 10 9.66 7.36
Protocol 1 versus protocol 2 %CD34+ cells, tube 1, day 10 14.45 13.09 <0.001
%CD34+ cells, tube 2, day 10 9.66 7.36
Table 4 The percentage of CD34+/CD31+ cells in mono-
nuclear cell suspension at day zero and day 10.
Culture number % CD34+/31+ cells
Day 0 Day 10
Initial count Control Tube 1 Tube 2
Mean 3.19 4.12 8.92 6.47
SD 3.18 3.82 6.16 4.94
Figure 3 Human cardiac control sections stained with: (a) Haemato
showing Cardiac troponin I positivity (cTnI+; Brown cytoplasmic sta
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CD31+ cells prior to culture (day zero) and at day 10
(Table 5):
There was a statistically signiﬁcant increase in the mean va-
lue of the CD34+/31+ cells on comparing day zero to the
control tube at day 10. Furthermore, a highly statistically sig-
niﬁcant increase in the mean value of CD34+/31+ cells was
noted on comparing day zero to day 10 in the control tube
and the cocktails used in tubes 1 and 2.
Table 6 Comparing the mean value of the % of CD34/31+
cells in day 10 in the control tube to those of the different
growth factors used showed that a highly statistically signiﬁ-xilin and Eosin, (b) Mouse anti-troponin I monoclonal antibody
ining).
Figure 4 Immunohistochemical staining of UCB-mononuclear
cells of the control tube following 10 days in culture media devoid
of cardiogenic inducers. Less than 2% of the cells could
differentiate into cardiomyocytes (cTnI negative cells).
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noted on comparing the control tube at day 10 to the cocktails
used in tubes 1 and 2 and there was a statistically signiﬁcant
decrease in the mean value of CD34/31+ cells between proto-
col 1 and protocol 2.
The percentage of Cardiac Troponin I (cTnI) positive cells
in UCB-mononuclear cell after day 10 in cardiogenic differen-
tiation media (Table 7, Figs. 3–6.
Statistical comparison between the percentage of cTnI+
cells in the control tube versus protocols 1 and 2 after 10 days
in cardiogenic differentiation media (Table 8):
Comparing the mean value of the percentage of cTnI+
cells in day 10 in the control tube to those in the different
growth factors used showed a highly statistically signiﬁcant in-Table 6 Statistical comparison between the percentage of CD34+
10 days in cardiogenic differentiation media.
Control tube versus protocol 1 %CD34+/31+ cells, control, day
%CD34+/31+ cells, tube 1, day
Control tube versus protocol 2 %CD34+/31+ cells, control, day
%CD34+/31+ cells, tube 2, day
Protocol 1 versus protocol 2 %CD34+/31+ cells, tube 1, day
%CD34+/31+ cells, tube 2, day
Table 5 Statistical comparison between the percentage of CD34+/
Control tube %CD34/31+ cells, day zero
%CD34/31+ cells, control, day 10
Protocol 1 (tube 1) %CD34/31+ cells, day zero
%CD34/31+ cells, tube 1, day 10
Protocol 2 (tube 2) %CD34/31+ cells, day zero
%CD34/31+ cells, tube 2, day 10crease in the mean value of cTnI+ cells noted on comparing
the control tube at day 10 to the cocktails used in tubes 1
and 2 as well as between the tube 1 and the tube 2.Discussion
Coronary artery diseases, i.e. acute myocardial infarction and
ischemic cardiomyopathy, are the main causes of death in most
of the developed countries and are a major socioeconomic
healthcare problem. Despite improved pharmacological ther-
apy and coronary revascularization procedures by either per-
cutaneous coronary intervention PCI or coronary artery
bypass surgery CABG there is still a major need for novel ther-
apeutic approaches [9].
It has, therefore, been a challenge in clinical research to ﬁnd
new treatment modalities that aim to reduce and repair the
myocardial damage and improve blood supply to the myocar-
dium in the ischemic heart. Regenerative medicine with vascu-
lar growth factor and stem cell therapy has within the last
decennium been of great interest and has been tested in clinical
trials in patients with ischemic heart disease. The aim is to in-
duce the growth of new blood vessels or the replacement of
damaged myocardial cells either directly by transdifferentia-
tion of stem cells or by a paracrine effect of cytokines secreted
from the stem cells [6].
In the absence of effective endogenous repair mechanisms
after cardiac injury, cell-based therapies have rapidly emerged
as a potential novel therapeutic approach in ischemic heart dis-
ease. A variety of stem and progenitor cells from different
sources have been examined for their potential to promote car-
diac repair and regeneration. At this stage, further optimiza-
tion of cell-based therapy is urgently needed, and ﬁnally,
large-scale clinical trials are required to eventually proove its
clinical efﬁcacy with respect to outcomes, i.e. morbidity and
mortality [15]./CD31+ cells in the control tube versus protocol 1 and 2 after
Mean Std. deviation Signiﬁcance (p value)
10 4.12 3.82 <0.001
10 8.92 6.16
10 4.12 3.82 <0.001
10 6.47 4.94
10 8.92 6.16 <0.001
10 6.47 4.94
CD31+ cells prior to culture (day zero) and at day 10.
Mean Std. deviation Signiﬁcance (p value)
3.19 3.18 <0.05
4.12 3.82
3.19 3.18 <0.001
8.92 6.16
3.19 3.18 <0.001
6.47 4.94
Table 7 The percentage of Cardiac Troponin I (cTnI) positive
cells in UCB-mononuclear cell after day 10 in cardiogenic
differentiation media.
Protocol 1 (tube 1) Protocol 2 (tube 2)
Mean 40.05 59.18
SD 8.99 10.99
NB: the control tube contains 62% cTnI+ cells (1.2 ± 0.8).
Figure 5 Immunohistochemical staining of in vitro differenti-
ated cardiomyocytes (cTnI positive cells; Brown staining of the
cytoplasm) from UCB-mononuclear cells after 10 days in cardio-
genic differentiation media (protocol 1).
Figure 6 Immunohistochemical staining of in vitro differenti-
ated cardiomyocytes (cTnI positive cells; Brown staining of the
cytoplasm) from UCB-mononuclear cells after 10 days in cardio-
genic differentiation media (protocol 2).
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source of many types of stem cells, including haematopoietic
stem cells (HSCs), endothelial progenitors, mesenchymal stem
cells (MSCs), very small embryonic/epiblast-like (VSEL) stem
cells, and unrestricted somatic stem cells (USSC), potentially
suitable for use in regenerative medicine [13].The transplantation studies carried out have demonstrated
that: (i) CB is an alternative source to the marrow of HSCs of
relatively easy procurement, with non-risk for mothers or do-
nors, and with a low risk of transmitting infectious diseases;
(ii) the number of CB cells available for transplantation is
the most important factor for engraftment; and (iii) some de-
gree of HLA mismatch is tolerated [4].
As cell therapy is a promising treatment modality to im-
prove the management of cardiovascular diseases, we per-
formed a study to deﬁne the optimal conditions for the
in vitro trans-differentiation of umbilical cord blood derived
stem cells into cardiomyocytes and endothelial cells. These
conditions include the combination of different cardiogenic
inducers as VEGF; FGF-2 and PDGF-AB.
In this study two protocols were applied for in vitro trans-
differentiation of cord blood stem cells. In protocol I, 40 cord
blood samples were expanded in a static liquid culture for
10 days to which serum was added, using VEGF and FGF-2
cocktail. In protocol II, PDGF-AB was added to protocol I
cocktail. This was intended to verify the effect of different car-
diogenic inducers such as VEGF; FGF-2 and PDGF-AB on
the trans-differentiation of umbilical cord blood derived stem
cells into cardiomyocytes and endothelial cells.
In the present work, the percentage of CD34+ cells,
CD31+ cells and CD34+/31+ cells in MNC suspension
was estimated prior to culture (day zero), and after day 10 in
the cardiogenic induction media with different cocktails of car-
diogenic inducers as well as the control tube, from which the
fold increase of CD34+ cells, CD31+ cells and CD34+/
31+ cells was calculated.
Cardiogenic differentiation was proved by the detection of
cardiac troponin I in the cultured cells at day 10 using Mouse
anti-troponin I monoclonal antibody.
Basic ﬁbroblast growth factor (bFGF or FGF-2) is a hepa-
rin-binding mitogenic protein that mediates the formation of
new blood vessels and enhances the proliferation of a wide
variety of cell types under serum-free or serum-reduced condi-
tions. bFGF is also known as a repressor of myoﬁbroblast dif-
ferentiation, which would be consistent with its effects on the
stimulation of Nkx2.5 expression and the consequent repres-
sion of a-SMA gene expression [10].
Hu et al. [5] showed that treatment of cells with bFGF sig-
niﬁcantly induced Nkx2.5 protein expression in a dose-depen-
dent manner. Nkx2.5 is a transcription factor with a well
known role as a promoter of cardiac cell differentiation and
a suppressor of a-SMA gene expression, and thus myoﬁbro-
blast differentiation.
Several studies have also demonstrated that the application
of multiple growth factors for therapeutic applications e.g.
VEGF, bFGF, angiopoietin-1 and PDGF has a greater impact
than single growth factor delivery [14].
Vascular endothelial growth factor (VEGF) is a mitogenic
and chemotactic factor for endothelial cells, and seems to play
a vital role in the protection of these cells against apoptosis.
The use of human VEGF as a potential stimulant in therapeu-
tic angiogenesis has been widely demonstrated. However, there
is still uncertainty as to whether the presence of human VEGF
alone would sufﬁce in the achievement of functional and ma-
ture vessels lined with vascular smooth muscles or pericytes [8].
Our study revealed that the different protocols conducted
for cardiogenic differentiation showed that there was a statis-
tically signiﬁcant increase in the mean value of CD34+ cells
Table 8 Statistical comparison between the percentage of cTnI+ cells in the control tube versus protocol 1 and 2 after 10 days in
cardiogenic differentiation media.
Mean Std. deviation Signiﬁcance (p value)
Control tube versus protocol 1 %cTnI+ cells, control, day 10 1.2 0.8 <0.001
%cTnI+ cells, tube 1, day 10 40.05 8.99
Control tube versus protocol 2 %cTnI+ cells, control, day 10 1.2 0.8 <0.001
%cTnI+ cells, tube 2, day 10 59.18 10.99
Protocol 1 versus protocol 2 %cTnI+ cells, tube 1, day 10 40.05 8.99 <0.001
%cTnI+ cells, tube 2, day 10 59.18 10.99
In vitro transdifferentiation of umbilical cord stem cells into cardiac myocytes: Role of growth factors 49on comparing the control tube at day 10 to the cocktails using
VEGF and bFGF in tube 1 and PDGF-AB in tube 2, and
there was a statistically signiﬁcant decrease in the mean value
of CD34+ cells between the two protocols (tube 1 and tube 2).
Moreover, our study revealed that the different protocols
conducted for cardiogenic differentiation showed that there
was a statistically signiﬁcant increase in the mean value of
CD34/CD31+ cells on comparing the control tube at day 10
to the cocktails using VEGF and bFGF in tube 1 and
PDGF-AB in tube 2, and there was a statistically signiﬁcant
decrease in the mean value of CD34/31+ cells between the
two protocols (tubes 1 and tube 2).
The peptide growth factor platelet-derived growth factor
(PDGF) consists of different combinations of two polypeptide
chains, A and B, which form homodimeric (PDGF-AA and
PDGF-BB) as well as heterodimeric (PDGF-AB) isoforms
binding to two structurally related protein tyrosine kinase
receptors, namely a- and b-receptors. Recently, two new
PDGF isoforms, namely PDGF-CC1 and PDGF-DD2 were
identiﬁed [1].
Binding to their cognate receptors results in the activation
of signaling cascades that initiates proliferation, migration,
and differentiation of a variety of cell types including ﬁbro-
blasts and smooth muscle cells [1].
During angiogenic processes, members of the PDGF family
act in concert with other pro-angiogenic factors, e.g. FGF-2,
to induce angiogenic synergy and vessel stability, suggesting
that combinatorial therapy with angiogenic and arteriogenic
factors may be utilized in therapeutic angiogenesis [12].
Recently, it has been shown that the stimulation of
PDGFR-b induced sprouting vasculogenesis in differentiating
embryonic stem (ES) cells, which form capillary-like structures
within the three-dimensional tissue of embryoid bodies and ex-
press the endothelial cell markers Flk-1 (VEGF-R2), ﬂt-1
(VEGF-R1), CD31, CD34, Tie-1, Tie-2, and VE-cadherin [3].
Our ﬁndings can be summarized as follows: cytokines cock-
tail in protocol 2 (FGF2+VEGF+PDGF-AB) gives better
in vitro trans-differentiation of stem/progenitor cells in umbil-
ical cord blood into cardiomyocytes and endothelial cells than
cytokines cocktail in protocol 1 (FGF2+VEGF) alone.
In conclusion, the use of cord blood CD34+ cells for cell-
based therapy should greatly simplify the procurement of cells
for the regeneration of damaged myocardium. Their use obvi-
ates the painful procedure of bone marrow aspiration and the
attendant anesthesia risks. In addition, autologous UCB stem
cell transplantation does not require long-term immune sup-
pressive therapy. Thus, the use of autologous UCB stem cellsfor myocardial regeneration is a promising alternative for the
treatment of heart failure after MI.
Summary and conclusion
The present study was intended to: (1) assess the potential use
of umbilical cord blood (UCB) for reproducible differentiation
into human cardiomyocytes and endothelial cells, (2) deﬁne the
role of using different growth factors in vitro to enhance the
differentiation capacity of UCB stem cells into cardiomyocytes
and endothelial cells.
The present study included UCB samples collected from the
obstetric ward of the Kasr Al-Aeini Hospital. Only full term,
completely normal, singleton pregnancies were included in this
study. 10–15 ml cord blood was obtained from the umbilical
vein with the placenta in utero after fetal delivery.
The data presented prove the feasibility of using UCB as a
source for human cardiac cells. In vitro culture of UCB with
the FGF-2 and VEGF promotes the differentiation of
CD34+ stem cells into endothelial cells and cardiomyocytes.
Further the addition of PDGF-AB will commit the endothelial
progenitor cellsCD31/CD34 transdifferentiation into
cardiomyocytes.
In conclusion, the existence of cardiac speciﬁc precursors in
the human umbilical cord paves the way to a possible cell ther-
apy approach for the restoration of cardiac function after
infarction, and improved knowledge on the biology of human
cardiac cell differentiation.
Recommendations
Clearly there is an unmet need for medical therapies in reduc-
ing morbidity and mortality in cardiovascular diseases. The
utilization of stem cells to augment or even to prevent advanc-
ing cardiovascular diseases is a subject that has great promise
as a modality to address these needs. UCB is a viable source of
stem cells due to its high content of CD34 and CD133 cells, as
well as its robust proliferative capacity, low immunogenicity,
low infectious contamination including virions, and the diverse
representation of HLA genotypes present in unrelated banked
UCB.
Further studies are required to develop well-deﬁned and
efﬁcient in vitro protocols for the cardiomyogenic differentia-
tion. This will provide the stringent levels of safety and quality
control that will make the clinical applications of stem cell
transplantation therapy realizable.
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